tbuckley/cabot-search huggingface dataset:
Suicide Among Children, Adolescents, and Young Adults—United States, 1980-1992
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erratum: Identifying and Prioritizing Chemicals with Uncertain Burden of Exposure: Opportunities for Biomonitoring and Health-Related Research
Authors: Edo D. Pellizzari, Tracey J. Woodruff, Rebecca R. Boyles, Kurunthachalam Kannan, Paloma I. Beamer, Jessie P. Buckley, Aolin Wang, Yeyi Zhu, Deborah H. Bennett
Journal: Environmental Health Perspectives (2021)
AMA-RPS Initiates Paper Recycling at Meetings
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Deep‐vein thrombosis and coumarin skin necrosis associated with a factor V inhibitor with lupus‐like features
Authors: Pieter W. Kamphuisen, Joost Haan, Peter C.M. Rosekrans, Felix J.M. Van Der Meer
Journal: American Journal of Hematology (1998)

We report a 71-year-old man who developed deep-vein thrombosis after major surgery. Coumarin skin necrosis developed after starting oral anticoagulant therapy. An inhibitor to factor V (61 Bethesda units) with lupus-like features was found as well as a low protein C level. The occurrence of these very rare findings indicates that despite profound procoagulant inhibition (factor V inhibition and anticoagulant therapy), hypercoagulation can occur. Am. J. Hematol. 57:176–178, 1998. © 1998 Wiley-Liss, Inc.
On Humility
Authors: Jack Coulehan
Journal: Annals of Internal Medicine (2010)

The new professionalism movement in medical education takes seriously the old medical virtues. Perhaps the most difficult virtue to understand and practice is humility, which seems out of place in a medical culture characterized by arrogance, assertiveness, and a sense of entitlement. Countercultural though it is, humility need not suggest weakness or lack of self-confidence. On the contrary, humility requires toughness and emotional resilience. Humility in medicine manifests itself as unflinching self-awareness; empathic openness to others; and a keen appreciation of, and gratitude for, the privilege of caring for sick persons. Justified pride in medicine's accomplishments should neither rule out nor diminish our humility as healers.
Birth Weight Reduction Associated with Residence near a Hazardous Waste Landfill
Authors: Michael Berry, Frank Bove
Journal: Environmental Health Perspectives (1997)

We examined the relationship between birth weight and mother's residence near a hazardous waste landfill. Twenty-five years of birth certificates (1961-1985) were collected for four towns. Births were grouped into five 5-year periods corresponding to hypothesized exposure periods (1971-1975 having the greatest potential for exposure). From 1971 to 1975, term births (37-44 weeks gestation) to parents living closest to the landfill (Area 1A) had a statistically significant lower average birth weight (192 g) and a statistically significant higher proportion of low birth weight [odds ratio (OR) = 5.1; 95% confidence interval (CI), 2.1-12.3] than the control population. Average term birth weights in Area 1A rebounded by about 332 g after 1975. Parallel results were found for all births (gestational age > 27 weeks) in Area 1A during 1971-1975. Area 1A infants had twice the risk of prematurity (OR = 2.1; 95 CI, 1.0-4.4) during 1971-1975 compared to the control group. The results indicate a significant impact to infants born to residents living near the landfill during the period postulated as having the greatest potential for exposure. The magnitude of the effect is in the range of birth weight reduction due to cigarette smoking during pregnancy.
Transposition of the Great Arteries
Authors: Jacqueline A. Noonan, Alexander S. Nadas, Abraham M. Rudolph, G. B. C. Harris
Journal: New England Journal of Medicine (1960)

Group 2-A (11 patients with defect of ventricular septum and pulmonic stenosis). Data for this group are summarized in Table 13.In no patient was a definite left-to-right shunt demonstrated at the atrial level. An increase in oxygen saturation occurred at the ventricular level in 6, whereas in 5 the increase in oxygen saturation was not noted until the aorta was sampled. It is assumed that the left-to-right shunt did occur at the ventricular level in the latter group as well. That the shunt did not occur at the ductal level is inferred from the fact that the pulmonary-artery pressure . . .
The Wisdom of Hindsight
Authors: M. Cohn
Journal: Annual Review of Immunology (1994)

This essay is a highly personalized account of some of the important conceptual contributions to immunology. I have asked myself, “What were the ideas that caught my attention and how and by whom were they presented?” I have learned that most of what immunologists have called concepts deal with too small a slice of the subject. They are essentially inductive extrapolations from one experiment to a possible next step. Historically, these extrapolations extended over too narrow a chasm to account for the information available at the time. The result was that an extrapolation from one misleading observation could dominate and distort, for a significant time, the course of the field. It is also why there has been an inverse relationship between the clarity of a theory and its ease of acceptance by immunologists. Looking to the past, I have used two areas to illustrate the role of conceptualization: the self-nonself discrimination and the origin of the humoral repertoire. To illustrate all of this I have chosen as a cast & characters the founding fathers of immunologays we know it today. I hope that by taking this look into the rear view mirror our efforts will be guided in more productive ways. The take-home lesson is that we need to widen our horizon constantly to make more general concepts that then render the manipulation of the immune system more useful.
Laboratory Tests: Misuse and Abuse
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
National Surveillance Program for Changes in Antimicrobial Susceptibilities
Journal: JAMA (1996)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reading disorders in children
Authors: L. J. Thompson
Journal: JAMA (1969)

<h3>To the Editor:—</h3> The importance of your editorial on reading disorders in children may not be fully appreciated by physicians (<b>206</b>:638, 1968). Authorities agree that about 10% of children (mostly boys) have some degree of specific reading disability or developmental dyslexia while only 3% are mentally retarded and about 5% have some speech disorder. Although reading disability is largely a problem for our schools, physicians are frequently called upon to participate in the diagnosis and recommendations. Yet many physicians are quite vague in their knowledge about reading disability. Your editorial helped to clarify the "diametrically opposed" concepts concerning developmental dyslexia. Much of the confusion arises from the fact that the majority of physicians, educators, and others think that disabilities in children must be due to either brain damage or emotional and environmental factors. For them it must be one or the other and they overlook or reject the possibility
Abstract 306: Endothelial Arnt Mediates Cardiac Remodeling After Ischemia Reperfusion Injury Through an MMP Pathway
Authors: Mei Zheng, Maura Knapp, Nikola Sladojevic, Anna Chen, Jorge Andrade, Qiong Zhao, James K Liao, Rongxue Wu
Journal: Circulation Research (2017)

Background: Prevention of myocardial injury following heart attack is a challenge due to lack of effective treatments and the potential to develop chronic heart failure (HF). Impaired endothelial function is thought to contribute to the progression of HF after cardiac ischemia-reperfusion injury (IR). However, the underlying mechanisms are unknown. Aryl Hydrocarbon Receptor Nuclear Translocator (ARNT), also known as hypoxia-inducible factor 1-beta (HIF1-β), plays a major role in vascular endothelial function and is implicated in ischemic diseases. We hypothesize that endothelial ARNT mediates cardiac remodeling following IR. Methods and Results: We generated inducible endothelial specific ARNT knockout mice (ecARNT -/- ) by crossing mice with loxP sequences flanking exon 6 of ARNT with Cre ERT2 mice under the VE-cadherin promoter. A 90% deletion of ecARNT was achieved following two weeks of oral tamoxifen administration. ecARNT -/- mice exhibit severe cardiac blood vessel leakage and impaired cardiac function after IR. Following 1 month of IR, ecARNT -/- mice had a 50% mortality rate, while no mortality was observed in the control group (ARNTf/f mice treated with tamoxifen). To determine the underlying mechanisms by which ARNT regulates endothelial function, we performed DNA sequencing on cardiac microvascular endothelial cells (CMECs) isolated from control and ecARNT -/- hearts. Data suggest a significant increase in the matrix metalloproteinases (MMP) family of proteins following ARNT knockdown. An increase in MMP activity in the serum of ecARNT -/- CMECs after IR was also detected. Moreover, use of an MMP inhibitor in vivo rescues heart failure induced by IR in ecARNT -/- mice. Taken together, these results suggest that ecARNT may mediate heart failure during IR through an MMP pathway. Conclusion: Endothelial ARNT is a critical regulator of endothelial function and could potentially serve as a therapeutic target for HF in response to IR injury.
UNDERNUTRITION IN COLLEGE WOMEN
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effect of baseline carbohydrate antigen 19-9 (CA19-9) level on overall survival (OS) in NAPOLI-1: A randomized phase III study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine (gem)-based therapy.
Authors: Li-Tzong Chen, Jens T Siveke, Andrea Wang-Gillam, Richard Hubner, Shubham Pant, Tomislav Dragovich, Vincent M. Chung, David Z. Chang, Paul J. Ross, Prasad Cooray, Niall C. Tebbutt, Fabio A. Franke, Bruce Belanger, Navreet Dhindsa, Floris de Jong, Khalid Mamlouk, Daniel D. Von Hoff
Journal: Journal of Clinical Oncology (2016)

e15740 Background: CA19-9 correlates with response to therapy and OS in patients with mPAC. NAPOLI-1 evaluated nal-IRI, a nanoliposomal formulation of irinotecan, with or without 5-FU/LV vs 5-FU/LV in mPAC patients previously treated with gem-based therapy. nal-IRI+5-FU/LV significantly improved OS (primary endpoint) vs 5-FU/LV (6.1 mo vs 4.2 mo; unstratified hazard ratio [HR] = 0.67; P = 0.012). CA19-9 response (≥50% decline from baseline) was superior with nal-IRI+5FU/LV vs 5-FU/LV (29% vs 9%; P = 0.0006). nal-IRI alone did not show a statistical improvement in OS. Methods: Patients with baseline CA19-9 measurements were divided into quartiles to evaluate the treatment effect pattern of CA19-9 in the nal-IRI+5-FU/LV and 5-FU/LV arms. Quartile ranges were based on 404 available CA19-9 values from randomized patients (N = 417). Unstratified Cox proportional hazards regression was used to estimate HRs and 95% confidence intervals (CIs). Effect of baseline CA19-9 on OS, time to response, progression-free survival (PFS), and response were assessed. Results: Of patients randomized to receive nal-IRI+5-FU/LV (n = 117) or 5-FU/LV enrolled contemporaneously (n = 119), 218 received study drug and had a baseline CA19-9 measurement. nal-IRI+5-FU/LV had a greater treatment effect on OS and PFS with higher CA19-9 level relative to 5-FU/LV. Higher treatment termination rates occurred in both study arms with higher CA19-9 quartile, but no patterns of subsequent therapy were observed. Conclusions: In patients with mPAC previously treated with gem-based therapy, nal-IRI+5-FU/LV significantly improved OS, supported by PFS and response rate. CA19-9 serum levels can provide important information with regard to OS. Clinical trial information: NCT01494506.CA19-9 level (U/ mL) Q1 < 120 Q2 120 to < 1549 Q3 1542 to < 12,815 Q4 ≥ 12,815 Median OS, mo (n) nal-IRI+5-FU/LV (n = 115) 7.6 (n = 27) 6.7 (n = 35) 6.1 (n = 27) 4.6 (n = 26) 5-FU/LV (n = 103) 7.2 (n = 31) 6.1 (n = 25) 3.8 (n = 21) 1.9 (n = 26) HR for Death (95% CI) 1.12 (0.57, 2.22) 0.74 (0.37, 1.48) 0.43 (0.22, 0.84) 0.35 (0.19, 0.64)
THE CULTIVATION OF ENDAMEBA HISTOLYTICA
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Costly "Cancer"?
Authors: CHARLES T. THORNSVARD
Journal: Annals of Internal Medicine (1974)

Comments1 March 1974Costly "Cancer"?CHARLES T. THORNSVARD, M.D.CHARLES T. THORNSVARD, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-80-3-422_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Alas: pocket books, $2.00; oil, windfall profits; andCancer Medicine(James Holland and Emil Frei, Lea and Febiger, Philadelphia) 1973, $92.00! I don't even mind the publication date—3 weeks before the certifying examination in oncology. Some public accounting, please?... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Walter Reed Army Medical Center Washington, D.C. 20012 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 March 1974Volume 80, Issue 3Page: 422-423KeywordsOils ePublished: 1 December 2008 Issue Published: 1 March 1974 PDF downloadLoading ...
How States are Legislating Workforce Planning, Part 1
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pten signaling in gliomas
Authors: C. B. Knobbe
Journal: Neuro-Oncology (2002)

In 1997, the PTEN gene (phosphatase and tensin homolog deleted on chromosome 10) was identi ed as a tumor suppressor gene on the long arm of chromosome 10.Since then, important progress has been made with respect to the understanding of the role of the Pten protein in the normal development of the brain as well as in the molecular pathogenesis of human gliomas.This review summarizes the current state of the art concerning the involvement of aberrant Pten function in the development of different biologic features of malignant gliomas, such as loss of cell-cycle control and uncontrolled cell proliferation, escape from apoptosis, brain invasion, and aberrant neoangiogenesis.Most of the tumor-suppressive properties of Pten are dependent on its lipid phosphatase activity, which inhibits the phosphatidylinositol-3 9 -kinase Pten signaling in gliomas 1,2
IF THE CAT SCRATCHES
Journal: JAMA (1960)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal